Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:AERI NASDAQ:DBVT NASDAQ:MESO NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.07+1.7%$2.81$1.78▼$8.56$63.37M0.9277,460 shs34,937 shsAERIAerie Pharmaceuticals$15.25$15.23$4.81▼$15.37$753.61M-0.06974,748 shs600 shsDBVTDBV Technologies$9.90+0.3%$9.71$2.20▼$12.78$270.39M-0.3632,815 shs72,334 shsMESOMesoblast$15.46+4.3%$14.57$6.00▼$22.00$1.90B2.26219,601 shs162,435 shsVCELVericel$31.42-2.4%$36.54$30.26▼$63.00$1.62B1.33669,483 shs1.22 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%AERIAerie Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DBVTDBV Technologies+0.30%+13.42%-0.90%+4.54%+172.84%MESOMesoblast+4.32%+6.25%-4.86%+31.35%+148.55%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.07+1.7%$2.81$1.78▼$8.56$63.37M0.9277,460 shs34,937 shsAERIAerie Pharmaceuticals$15.25$15.23$4.81▼$15.37$753.61M-0.06974,748 shs600 shsDBVTDBV Technologies$9.90+0.3%$9.71$2.20▼$12.78$270.39M-0.3632,815 shs72,334 shsMESOMesoblast$15.46+4.3%$14.57$6.00▼$22.00$1.90B2.26219,601 shs162,435 shsVCELVericel$31.42-2.4%$36.54$30.26▼$63.00$1.62B1.33669,483 shs1.22 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%AERIAerie Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DBVTDBV Technologies+0.30%+13.42%-0.90%+4.54%+172.84%MESOMesoblast+4.32%+6.25%-4.86%+31.35%+148.55%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.75Moderate Buy$19.75543.32% UpsideAERIAerie Pharmaceuticals 0.00N/AN/AN/ADBVTDBV Technologies 2.80Moderate Buy$14.7548.99% UpsideMESOMesoblast 3.20Buy$18.0016.43% UpsideVCELVericel 3.00Buy$60.4092.23% UpsideCurrent Analyst Ratings BreakdownLatest ADVM, VCEL, DBVT, AERI, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.008/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/1/2025VCELVericelCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$61.00 ➝ $58.007/18/2025MESOMesoblastJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $12.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$67.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M64.41N/AN/A$3.40 per share0.90AERIAerie Pharmaceuticals$194.13M3.88N/AN/A($3.32) per share-4.59DBVTDBV Technologies$4.15M65.36N/AN/A$1.42 per share6.97MESOMesoblast$17.20M115.05N/AN/A$4.67 per share3.31VCELVericel$237.22M6.68$0.31 per share102.98$5.92 per share5.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)AERIAerie Pharmaceuticals-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/ADBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/AVCELVericel$10.36M$0.12261.8671.41N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest ADVM, VCEL, DBVT, AERI, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAERIAerie PharmaceuticalsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54AERIAerie PharmaceuticalsN/A2.271.92DBVTDBV TechnologiesN/A2.452.45MESOMesoblast0.111.991.77VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%AERIAerie Pharmaceuticals95.94%DBVTDBV Technologies71.74%MESOMesoblast1.43%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%AERIAerie Pharmaceuticals4.44%DBVTDBV Technologies1.44%MESOMesoblast18.80%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableAERIAerie Pharmaceuticals37649.42 million47.22 millionOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableVCELVericel30050.46 million46.83 millionOptionableADVM, VCEL, DBVT, AERI, and MESO HeadlinesRecent News About These CompaniesVericel (NASDAQ:VCEL) Shares Down 5.8% - Here's WhySeptember 12, 2025 | marketbeat.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comJacobs Levy Equity Management Inc. Purchases Shares of 62,938 Vericel Corporation $VCELSeptember 12, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Vericel Stock?September 11, 2025 | zacks.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?September 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 25,600 Shares of Vericel Corporation $VCELSeptember 10, 2025 | marketbeat.comRoyal Bank of Canada Boosts Stock Holdings in Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comTrexquant Investment LP Sells 57,615 Shares of Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comVericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage RepairSeptember 7, 2025 | tipranks.comVericel Corporation $VCEL Shares Bought by PDT Partners LLCSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Invests $723,000 in Vericel Corporation $VCELSeptember 3, 2025 | marketbeat.com9,769 Shares in Vericel Corporation $VCEL Bought by Jump Financial LLCSeptember 3, 2025 | marketbeat.comVericel Corporation $VCEL Stock Position Decreased by Raymond James Financial Inc.August 31, 2025 | marketbeat.comNext Century Growth Investors LLC Boosts Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Lowers Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | markets.businessinsider.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | globenewswire.comNuveen LLC Purchases New Position in Vericel Corporation $VCELAugust 28, 2025 | marketbeat.comWellington Management Group LLP Acquires 74,723 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 31,635 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comVanguard Group Inc. Purchases 7,978 Shares of Vericel Corporation $VCELAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADVM, VCEL, DBVT, AERI, and MESO Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.07 +0.05 (+1.66%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.08 +0.01 (+0.16%) As of 09/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Aerie Pharmaceuticals NASDAQ:AERIAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.DBV Technologies NASDAQ:DBVT$9.79 -0.08 (-0.80%) As of 09/15/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Mesoblast NASDAQ:MESO$15.46 +0.64 (+4.32%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$15.86 +0.40 (+2.55%) As of 09/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Vericel NASDAQ:VCEL$31.42 -0.76 (-2.36%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$31.42 -0.01 (-0.02%) As of 09/15/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
